See the DrugPatentWatch profile for cosentyx

Patient satisfaction can significantly influence a drug's market share, including how Cosentyx (secukinumab) fares against Humira (adalimumab) in the autoimmune disease treatment market.

Patient satisfaction is a crucial factor in medication adherence and persistence [1]. When patients are satisfied with their treatment, they are more likely to adhere to the prescribed regimen, which can lead to better health outcomes. Consequently, higher patient satisfaction can potentially increase a drug's market share.

Cosentyx, a drug developed by Novartis, is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A) [2]. It is indicated for the treatment of several autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [2].

Humira, developed by AbbVie, is a tumor necrosis factor (TNF) inhibitor that is also used to treat various autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [3].

According to DrugPatentWatch.com, Cosentyx has several patents that extend its exclusivity in the US market until 2026 [4]. Meanwhile, Humira's patents have expired in Europe, leading to biosimilar competition [5]. This exclusivity could contribute to Cosentyx's market share growth.

Moreover, a network meta-analysis published in the British Journal of Dermatology found that Cosentyx was more effective than Humira in treating moderate-to-severe psoriasis [6]. This could potentially lead to higher patient satisfaction and increased market share for Cosentyx.

In summary, patient satisfaction can significantly influence a drug's market share. Cosentyx's exclusive patents and superior efficacy compared to Humira in treating psoriasis could contribute to higher patient satisfaction and increased market share.

Sources:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157007/
[2] https://www.novartis.com/sites/www.novartis.com/files/cosentyx-pi.pdf
[3] https://www.abbvie.com/products/humira-adalimumab.html
[4] https://www.drugpatentwatch.com/drugs/secukinumab
[5] https://www.drugpatentwatch.com/drugs/adalimumab
[6] https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.17844